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BACKGROUND: The PI3K/Akt signalling pathway, induced by epidermal growth factor receptor (EGFR) and Her-2, is involved in the
constitutive activation of NF-kB in prostate cancer cell lines. In this study, we extended the in vitro observation using an ex vivo model
of prostate cancer tissues and assessed the prognostic significance of the PI3K/Ak/NF-kB signalling determinants.
METHODS: We analysed a prostate cancer tissue microarray of 63 patients for the expression of total and activated EGFR, Her-2
receptors and the signalling molecules PTEN, phospho-PTEN, Akt, phospho-Akt and the NF-kB subunit p65. Data were analysed
using Spearman’s rho test, Kaplan–Meier curves and multivariate Cox regression analysis. In addition, a non-supervised hierarchical
clustering analysis was applied to stratify patients according to prognostic groups in terms of risk of recurrence.
RESULTS: The concomitant overexpression of activated EGFR and Her-2 was correlated with the nuclear expression of NF-kB. EGFR,
phospho-EGFR, phospho-Her-2, ErbB3 and nuclear NF-kB were associated with the overall biochemical recurrence (BCR) of
patients. The non-supervised hierarchical clustering analysis resulted in the separation of patients into five groups according to BCR.
CONCLUSIONS: These results validate the previous in vitro data on ErbB involvement in NF-kB activation and shows evidence for a
significant role of ErbB/PI3K/Akt/NF-kB signalling in the progression of prostate cancer.
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Prostate cancer is a leading cause of cancer death in men (Jemal
et al, 2009). Treatment of prostate cancer depends on its stage at
diagnosis. When diagnosed at an early stage, and if the patient
is healthy, aggressive therapy is often recommended. However,
some early-stage tumours will remain latent and will not require
aggressive therapy, whereas others are at risk of progression and
need to be treated early. It is unclear what genes or proteins are
implicated in the initiation and progression of prostate cancer.
Recently, we, along with others, have shown that the p65 subunit of
the nuclear factor-kB (NF-kB) transcription factor seems to have a
role in the development of prostate cancer and in its progression to
an advanced disease (Lessard et al, 2003, 2006; Ismail et al, 2004;
Shukla et al, 2004).
Nuclear factor-kB proteins exist as homo- and heterodimers
expressed in many cell types but are kept inactive and maintained
in the cytoplasm by the IkB family of inhibitors. Classically, the
activation of NF-kB requires intracellular signals that combine
to activate the trimeric IkB kinase complex (IKK), resulting in
the phosphorylation of IkBa and its subsequent ubiquitinylation.
The net result of this process is translation to the nucleus of NF-kB
(Gasparian et al, 2002). A constitutive activation of the PI3K/Akt
pathway through IKK has been implicated in this activation of
NF-kB in the PC-3 hormone-independent prostate cancer cell
line (Gustin et al, 2001; Gasparian et al, 2002; Mayo et al, 2002;
Le Page et al, 2005b). The activation of PI3K results in the
translocation of Akt from the cytoplasm to the inner membrane,
where Akt is phosphorylated by upstream kinases, PDK and ILK.
On the other hand, phosphatase PTEN inhibits the kinase activity
of PI3K and thereby suppresses the activation of downstream
targets such as Akt. The activation of Akt leads to the
phosphorylation of downstream targets such as IKK, GSK3, Bad,
mTOR, caspase 9 and the FOXO family of forkhead transcription
factors (Vivanco and Sawyers, 2002). More recently, we provided
evidence that the epidermal growth factor receptor (EGFR)
signalling pathway is implicated as an early event that constitu-
tively activates the PI3K/Akt/NF-kB pathway in PC-3 prostate
cancer cells (Le Page et al, 2005b).
Epidermal growth factor receptor and Her-2 are members of the
ErbB growth factor receptor family composed of four distinct
receptors: EGFR/ErbB1, Her-2/ErbB2/c-neu, Her-3/ErbB3 and
Her-4/ ErbB4. In PC-3 cells, EGFR and Her-2 overexpression and
constitutive activation modulate NF-kB signalling through two
distinct mechanisms: one dependent and one independent of
the phosphorylation of IkBa on ser32/ser36 (Le Page et al, 2005b).
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sIn PC-3 cells, EGFR, but not Her-2, activates NF-kB through
the PI3K/Akt pathway, which induces the phosphorylation of
IkBa on ser32/ser36 and the subsequent nuclear translocation
of NF-kB. Independently, Her-2 also activates NF-kB through
the CK2 pathway (Le Page et al, 2005b). The two signalling
pathways function additively, allowing a stronger activation of
NF-kB (Le Page et al, 2005a,b). In addition, ErbB3 has been
shown to constitutively activate the PI3K pathway in prostate
cancer cell lines (Lin et al, 1999; Jung et al, 2006), which may also
lead to the constant NF-kB activation in prostate cancer cells.
In this study, we sought to extend these in vitro studies by an
ex vivo analysis of the determinants of EGFR and Her-2 signalling
in NF-kB activation in prostate cancer tissues. For this purpose,
we used specific antibodies and immunohistochemistry (IHC)
to evaluate the profile of expression of EGFR, Her-2, ErbB3, PI3K,
PTEN, Akt, p65 and their phosphorylated forms. The staining
with phospho-ErbB3 antibody was too weak to be analysed and
was thus not included in this study. Statistical correlations of the
protein expression in tissues allowed us to associate signalling
events according to the activation of EGFR, Her-2 and PTEN, as
well as that of p65. Indeed, this also allowed us to conduct
hierarchical analysis to provide a holistic view of pathway
interactions and their association with prognosis. This is the first
systematic analysis of ErbB receptors and the downstream
signalling pathway PI3K/Akt in prostate cancer tissues.
MATERIALS AND METHODS
Patient cohort
Paraffin-embedded human primary PCa specimens (collected blocks
from 1993 to 2000) from patients who provided informed consent
were reviewed. A total of 64 specimens from patients who had a
radical prostatectomy were included in our study to create a tissue
array. Criteria for the retrospective cohort study to create tissue
arrays were the following: (a) no pre- or postoperative treatment was
used before biochemical recurrence (BCR) and (b) all cases had a
clinical follow-up of at least 3 years or until death. Patients were
followed for an average range of 72 months. No age difference was
observed between the group of patients who relapsed and the group
who did not. Preoperative prostate-specific antigen (PSA) levels were
available for 62 patients. Postoperative PSA was available for all
patients. Non-failure of PSA was defined as PSA remaining below
0.3ng/ml after radical prostatectomy. Recurrence-free interval was
defined as the time between the date of surgery and the date of first
PSA increase above 0.3ng/ml. The final staging, grading and
histological diagnosis were based on the Ho ˆpital Notre-Dame
(Montreal, Canada) pathology department report in agreement
with the review by an independent pathologist. Ethics approval
was obtained from the local IRB committee.
Tissue arrays, immunohistochemistry, scoring and
immunoblotting
Tissue arrays containing a total of 384 cores of prostate tissues
(Table 1) were built and used for IHC studies. One normal and
two cancerous cores per patient were spotted on one array and
a duplicate of this array was made, giving a total of six cores per
patient. An expert pathologist reviewed and determined the
cancerous, non-neoplastic prostatic epithelium and PIN areas of
H&E-stained arrays. However, 11 cores that contained neither
cancerous tissues nor non-neoplastic adjacent tissues were not
considered for further analysis. The final analysis contained 373
tissue cores representing 63 patients. All patients were represented
by at least two cancer cores.
In brief, tissue arrays were deparaffinised in toluene and
rehydrated in a gradient of ethanol. Subsequently, endogenous
peroxidase activity was quenched by treatment with 0.3% H2O2/
methanol. To unmask antigen, the slides were submerged in 951C
citrate buffer (10mM, pH 6.0) or in EDTA buffer (1mM, pH 8.0) for
15min. The tissues were blocked for 15min with a protein-
blocking, serum-free reagent (Dako Cytomation Inc., Mississauga,
ON, Canada) and incubated with different antibodies for 60min at
room temperature in a humid chamber. The optimal concentration
for each primary antibody was determined by serial dilutions. The
arrays were then incubated with a secondary biotinylated antibody
(Dako Cytomation) for 15min, followed by incubation with a
streptavidin–peroxidase complex (Dako Diagnostics Canada Inc.,
Mississauga, ON, Canada). Reaction products were developed using
diaminobenzidine (brown stain) containing 0.3% H2O2 as a substrate
for peroxidase. Nuclei were counterstained with diluted haematoxylin
(blue stain). Tumour sections were inspected at  20 and  40
magnification. Epithelial zones were scored according to the
staining intensity of the cytoplasm, nucleus or membrane (value of
0 for absence, 1 for weak, 2 for moderate and 3 for high intensity).
In cores in which staining was of variable intensity, the average
intensity was reported. Each array was independently analysed in a
blind study by two independent observers. Interrating correlation
was 470%. When strong differences in scoring between the two
observers (more than 1 unit per core) occurred, the core was
re-evaluated to reach a concordant scoring between the two
observers. The average of all cores with cancer from the same
patient was used for analysis. No decrease in staining intensity on
older paraffin blocks was observed.
The antibodies and conditions used in IHC are summarised
in Supplementary Table 1. The specificity of antibodies was
previously tested by immunoblotting and showed only one specific
band (Supplementary Figure 1). Immunoblotting procedures have
been described elsewhere (Le Page et al, 2005a,b; Koumakpayi
Table 1 Description of the prostate cancer patient cohort
Age median (min–max) 62 (49–70)
Stage
Stage 2 34
Stage 3 29
Invasion
Extracapsular invasion 19
Lymph node invasion 9
Peri-neural infiltration 9
Hormone refractory disease 5
Prostatis 1
Gleason score
Gleason 4 7
Gleason 5 14
Gleason 6 14
Gleason 7 18
Gleason 8 and 9 10
Pre-operative PSA
o10ng 35
410ng 25
Not available 2
PSA relapse
Relapse 35
No relapse 28
Surgical margins
Negative 31
Positive 32
Survival 54
Abbreviation: PSA¼prostate-specific antigen.
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set al, 2006). In brief, cells were lysed with cold lysis buffer (10mM
Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1mM DTT/1mM
NaF/0.5% NP-40/ 0.5mM PMSF/0.2mM sodium orthovanadate/
2mgml
–1of aprotinin, leupeptin and pepstatin), boiled in loading
buffer, separated by SDS–PAGE and transferred on a nitro-
cellulose membrane under refrigerated conditions (60V for 2h).
The membrane was saturated with 5% milk/PBS/0.1% Tween-20.
Immunodetection was carried out as described in the protocol of
the ECL kit (Amersham Pharmacia, Little Chalfont, UK). Membranes
were incubated for 2h at room temperature with the specific
antibody (0.5–1mgml
–1), washed twice with PBS/0.05% Tween-20
and incubated for another 30min at room temperature with
peroxidase-conjugated antibodies (Santa-Cruz Biotechnology Inc.,
Santa Cruz, CA, USA).
Statistical analysis and non-supervised hierarchical
clustering analysis
Statistical analysis was carried out with SPSS software 11.0 (SPSS
Inc., Chicago, IL, USA). To avoid bias due to a different efficiency
of antibody hybridisation on different array slides, we calibrated
each slide for interslide comparison. Spearman’s rho correlation
test (two tailed) was used to estimate the correlation with clinico-
pathological variables. Survival curves were plotted using the
Kaplan–Meier analysis and the log-rank test was used to test for
significant differences. Receiver operative characteristic (ROC)
curves were used to determine the threshold value for each marker.
Cox univariate and multivariate proportional hazard models were
used to estimate the hazard ratio for each marker. Multivariate
analysis was carried out using a forward stepwise hazard model
on univariate analysis required for entry into the model. Only
three categorical variables were included in the multivariate
Cox regression model to avoid an overfitting situation. These
variables were chosen on the basis of their significance in the
univariate model and were as follows: surgical margins, Gleason
score and pathological stage.
We carried out hierarchical clustering analysis using Genespring
software (Silicon Genetics, Santa Clara, CA, USA) on the filtered
data set. We used the distance branch of 0.8 with a Pearson
correlation as a similarity metric.
RESULTS
Expression level and localisation of EGFR, Her-2, ErbB3
and their phosphorylated forms
Membrane and cytoplasmic reactivity rates were evaluated in
samples of 63 prostate cancer patients (cohort described in
Table 1). All cores showed detectable staining for EGFR, phospho-
EGFR, Her-2, phospho-Her-2 and ErbB3, mainly localised in the
membrane and cytoplasm of cell tissue (Figure 1 and Supplemen-
tary Table 2). We did not observe any nuclear staining with EGFR
and Her-2, but we observed nuclear localisation of ErbB3 as
previously described (Gannon et al, 2008) and of phospho-Her-2.
Out of 63 patients, 42 showed nuclear ErbB3 presence in cancerous
tissues. Only four patients showed weak staining (below 1) for
EGFR (Supplementary Table 2). Three of these patients also
showed a concomitant weak staining for phospho-EGFR. Similarly,
only one patient showed weak staining for Her-2, which was
associated with a weak staining of phospho-Her-2. It is noteworthy
that only one patient showed a weak phospho-EGFR signal when
a strong EGFR signal was observed. The same patient also showed
a strong Her-2 expression but a weak phospho-Her-2 staining.
In general, a very strong correlation between EGFR and
phospho-EGFR staining, and between Her-2 and phospho-Her-2
staining, was found (r¼0.63 and r¼0.45, respectively, Po0.001,
Spearman’s rho test; Table 3). Similarly, EGFR staining was also
often associated with Her-2 and ErbB3 staining (r¼0.42 P¼0.001
and 0.56 Po0.001, respectively) and a very strong correlation was
obtained between phospho-EGFR and phospho-Her-2 (r¼0.73,
Po0.001). A slightly weaker correlation was observed between
Her-2 and ErbB3 (r¼ 0.0.38, P¼0.002).
In 65% of patients (41 of 63), cancer tissues showed an
overexpression of EGFR compared with normal tissues, whereas 79
and 81% (50 of 63 and 51 of 63, respectively) of patients showed
an overexpression of cytoplasmic Her-2 and ErbB3, respectively
(Supplementary Table 2). These results suggest that Her-2 and
ErbB3 are overexpressed more often than EGFR in prostate cancer
Figure 1 Representative staining for immunohistochemistry of EGFR,
Her-2 and ErbB3 in prostate cancer tissues. (A, C) Low and moderate
EGFR and phospho-EGFR cytoplasmic staining, respectively. (B, D) EGFR
and phospho-EGFR strong cytoplasmic immunostaining, respectively.
(E, G) Low and moderate staining for Her-2 and phospho-Her-2,
respectively. (F) Strong cytoplasmic Her-2 staining. (H) Strong cytoplasmic
staining with nuclear staining for phospho-Her-2. (I) Moderate cytoplasmic
ErbB3 staining. (J) Strong cytoplasmic and moderate nuclear ErbB3 staining.
Each individual marker is indicated. Magnification  20.
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stissues. However, a similar number of patients overexpressed
phospho-EGFR and phospho-Her-2 (70 and 73%, respectively).
Expression and localisation of PI3K/PTEN/AKT pathway
members
We also evaluated the activation status of the Akt/PI3K and NF-kB
signalling pathway. For this purpose, we immunostained the tissue
arrays with antibodies against phospho-Akt, PTEN, phospho-
PTEN (Figures 2 and 3). Phospho-Akt and Akt expressions have
already been described on this TMA (Le Page et al, 2006). In brief,
membrane, cytoplasmic and nuclear staining was observed for Akt
and for its activated form phospho-Akt. Staining of Akt and
phospho-Akt was strongly associated (r¼0.70, Po0.001; Table 3)
and both were overexpressed in 460% of patient tumours.
Expression of PTEN was observed in 61 out of 63 prostate
cancer patients analysed. A total of 13 patients (20%) had a strong
PTEN staining (X2.5) and only two patients showed a very weak
(o0.5) or an absence of PTEN staining (Supplementary Table 2).
Similarly, phospho-PTEN staining was observed in 59 out of
63 patients and was correlated with PTEN staining (r¼0.40,
P¼0.001, Spearman’s test; Table 3). However, 4 out of 10 patients
with a weak PTEN staining showed a strong phospho-PTEN
staining (Supplementary Table 3). PTEN was mainly expressed in
the cytoplasm but a few tissue specimens also showed nuclear
staining. Phospho-PTEN was present in both cytoplasmic and
nuclear compartments. The expression of phospho-PTEN was
decreased in patients with Gleason scores 46 and negatively
correlated with Gleason scores (r¼  0.286, P¼0.023; Table 2).
In 45 out of 63 cases (71%), PI3K was highly overexpressed in
tumour tissues compared with adjacent normal tissues. Only two
patients presented a weak PI3K staining (below average intensity
1 on 2 cores). PI3K staining was exclusively cytoplasmic. The
intensity of PI3K staining was strongly associated with the
expression of PTEN, phospho-PTEN and phospho-Akt (r¼0.59,
r¼0.70, r¼0.59, and Po0.001, respectively; Table 3).
Expression and localisation of p65 and correlation with
EGFR, Her-2 and ErbB3 pathways
The p65 subunit of NF-kB was expressed in the cytoplasm of all
examined prostate cancer tissues (Figure 3 and Supplementary
Table 2). Some tissues (n¼45, 70%) also showed a nuclear
staining of p65, suggesting a constitutive activation of NF-kBi n
these tissues. Phospho-p65 was present in the cytoplasm and a
weak staining could be observed in a few cells.
The presence of p65 in the nucleus of prostate cancer tissues was
evaluated by the percentage of cells with a nuclear p65 staining.
A mean of 2% of cells per tissue showed a p65 nuclear staining.
In eight patients, cancer tissues had 410% positive nuclei.
Interestingly, the presence of nuclear p65 was increased in
patients with Gleason scores of 46, and globally correlated with
Gleason scores (r¼0.28, P¼0.026 Spearman’s test, Table 2). There
was no statistical correlation between cytoplasmic and nuclear
p65 (r¼0.11, P¼0.37), as well as between phosphorylated p65 and
nuclear p65 (Table 3, r¼0.12, P¼0.343), even when the staining of
phospho-p65 and cytoplasmic p65 strongly correlated (Table 3,
r¼0.53, Po0.001).
We also evaluated the correlation between nuclear p65 and
EGFR, Her-2 and ErbB3 expression. Surprisingly, the presence of
nuclear p65 did not correlate with EGFR, Her-2 or ErbB3, either
Figure 2 Representative staining for immunohistochemistry of PI3K/Akt/
PTEN signalling pathway markers in prostate cancer tissues. (A, B) Low
and strong cytoplasmic PI3K immunostaining. (C) Low cytoplasmic staining
for PTEN. (D) Strong cytoplasmic staining and nuclear staining of PTEN.
(E) Phospho-PTEN low cytoplasmic staining. (F) Strong cytoplasmic
staining with high nuclear staining of phospho-PTEN. (G) Moderate
cytoplasmic p-Akt staining. (H) Strong cytoplasmic staining with nuclear
p-Akt (top right corner). Each individual marker is indicated. Magnification
 20.
Figure 3 Representative staining for immunohistochemistry of p65/RelA
in prostate cancer tissues. (A) Strong cytoplasmic staining with no nuclear
staining of NF-kB p65 subunit. (B) Moderate and strong cytoplasmic
staining with nuclear NF-kB p65 subunit. (C) Low and moderate phospho-
NF-kB p65 subunit. (D) Moderate and strong phospho-NF-kB p65 subunit
cytoplasmic staining with nuclear staining. Each individual marker is
indicated. Magnification  20.
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salone or with any other proteins tested (ro0.06, P40.05) when
continuous values were considered. However dichotomised values
of nuclear p65 (high and low) did correlate with combined EGFR
and Her-2 (r¼0.25, P¼0.047).
Correlation with clinical parameters
We evaluated the correlation between a strong staining of each
antibody and the clinical parameters available for the patient
cohort. No correlation was observed between any staining and
metastatic spread, perineural infiltration or age (Table 2). In
contrast, a strong staining of phospho-EGFR, phospho-Her-2
and nuclear NF-kB correlated with disease stage (r¼0.32, 0.36,
0.32 and P¼0.012, 0.004, 0.011, respectively). A trend towards
significance was observed for EGFR and ErbB3 (r¼0.21 0.22,
P¼0.09 and 0.08, respectively). Both phospho-PTEN and nuclear
p65 correlated with the Gleason score (r¼ –0.29, P¼0.023 and
r¼0.28, P¼0.026). Only phospho-PTEN was significantly and
inversely correlated with death due to prostate cancer (r¼ 0.32,
P¼0.011) and a positive trend was observed with nuclear
Table 2 Spearman’s correlation between markers and clinicopathological parameters
P EGFR P-EGFR Her2 P-Her2 ERBB3 PTEN P-PTEN P65 P-p65 P65 nucl PI3K CLUSTER
LN
Correlation coefficient 0.013 0 0.091  0.04  0.014  0.118  0.411  0.096  0.132 0.238  0.177  0.128
P 0.919 1 0.477 0.757 0.914 0.355 0.001 0.453 0.301 0.06 0.166 0.319
Metastasis
Correlation coefficient 0.271  0.042 0.144  0.122 0.074 0.127  0.122 0.208 0.118 0.171  0.031 0.075
P 0.032 0.747 0.259 0.341 0.564 0.322 0.341 0.103 0.357 0.179 0.808 0.559
N 63 63 63 63 63 63 63 63 63 63 63 63
PSA
Correlation coefficient 0.131 0.032 0.059 0.113  0.041  0.294  0.042  0.137  0.142 0.179  0.135 0.198
P 0.316 0.805 0.652 0.384 0.756 0.022 0.748 0.292 0.275 0.168 0.3 0.126
Age
Correlation coefficient 0.008  0.033 0.055 0.054 0.079  0.153  0.13  0.069  0.236  0.154 0.11 0.098
P 0.951 0.795 0.671 0.676 0.538 0.231 0.311 0.593 0.062 0.229 0.39 0.445
Gleason
Correlation coefficient  0.008 0.042  0.17 0.05  0.076  0.09  0.286  0.166 0.044 0.281  0.092  0.116
P 0.95 0.746 0.183 0.696 0.555 0.484 0.023 0.194 0.733 0.026 0.474 0.367
Invasion
Correlation coefficient 0.121 0.318  0.178 0.392 0.225  0.152 0.038  0.122  0.174 0.304  0.026 0.022
P 0.344 0.011 0.163 0.002 0.076 0.235 0.767 0.34 0.173 0.015 0.837 0.867
Margin
Correlation coefficient 0.238 0.382  0.05 0.5 0.215  0.051 0.045  0.09  0.149 0.374  0.188 0.1
P 0.061 0.002 0.699 0 0.09 0.69 0.724 0.484 0.243 0.003 0.14 0.435
Stage
Correlation coefficient 0.214 0.315  0.071 0.359 0.219  0.002  0.032  0.09  0.097 0.319  0.125 0.05
P 0.092 0.012 0.579 0.004 0.084 0.987 0.803 0.483 0.449 0.011 0.329 0.699
Grade
Correlation coefficient  0.037 0.012  0.196 0.014  0.12  0.11  0.307  0.192 0.084 0.311  0.06  0.117
P 0.771 0.925 0.123 0.915 0.348 0.391 0.014 0.132 0.512 0.013 0.639 0.361
Infiltra
Correlation coefficient 0.195 0.192 0.091 0.238 0.084  0.026  0.04  0.096 0.053 0.134  0.082 0.079
P 0.126 0.131 0.477 0.06 0.515 0.838 0.757 0.453 0.68 0.295 0.525 0.54
BPH
Correlation coefficient  0.162  0.046  0.123 0.061  0.144  0.177  0.005  0.252  0.072 0.101  0.018  0.013
P 0.204 0.721 0.336 0.635 0.261 0.166 0.967 0.046 0.577 0.433 0.886 0.92
Death
Correlation coefficient 0.195 0 0.091  0.132 0.084 0.066  0.318 0.096  0.04 0.238 0.014  0.012
P 0.126 1 0.477 0.301 0.515 0.608 0.011 0.453 0.757 0.06 0.916 0.928
Recurrence
Correlation coefficient 0.359 0.272 0 0.281 0.236  0.074 0.084 0.068 0.019 0.305  0.163 0.198
P 0.004 0.031 1 0.026 0.062 0.562 0.511 0.596 0.884 0.015 0.201 0.12
Abbreviations: LN¼lymph node infiltration; PSA¼prostate-specific antigen before surgery; Invasion¼extra-capsular invasion; margin¼surgical margin; Infiltration¼peri-neural
infiltration; BPH¼benign hyperplasia; BCR¼biochemical recurrence; p65 Cyto¼cytoplasmic staining of p65; p65 nuc¼ nuclear p65 staining; Cluster¼cluster of non-
supervised hierarchical analysis (combination of marker allowing clustering of patients in five groups); Rho¼Spearman’s coefficient correlation. Significant correlations (Po0.05)
are indicated by bold numbers.
EGFR, Her-2 and ErbB3 signalling in prostate cancer tissue
IH Koumakpayi et al
1167
British Journal of Cancer (2010) 102(7), 1163–1173 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sp 6 5s t a i n i n g( r¼0.24, P¼0.06) and phospho-Akt (r¼0.22, P¼0.08;
Le Page et al, 2006). However, the significance of this result should be
taken in consideration with the relatively low mortality rate (n¼9) in
this cohort of radical prostatectomy patients.
Association with biochemical recurrence
To evaluate the association between the expression of each protein
and the BCR of prostate cancer patients in our cohort, we
performed Kaplan–Meier curve analysis coupled with log-rank
test and univariate Cox regression analysis. Figure 4 shows the
Kaplan–Meier curves obtained. Table 4 shows regression analysis
results. Of the candidates listed, EGFR, ErbB3, phospho-EGFR,
phospho-Her-2 and nuclear NF-kB were associated with the
overall BCR. Phospho-Akt showed a strong trend to associate
with BCR (P¼0.058). In addition, phospho-Akt and PI3K were
significantly associated with early BCR at 2 years but not with
overall BCR (P¼0.03 and P¼0.02, respectively, data not shown).
EGFR staining was the most significant event associated with BCR
(log rank P¼0.004 and HR¼2.75, P¼0.05). No combination of
proteins, either phosphorylated receptors or signalling proteins,
was more significant than EGFR alone (data not shown). In
addition, only EGFR was statistically significant in multivariate
Cox regression analysis when Gleason score, margin status and
pathological stage were considered in the model (P¼0.03, CI 95%
1.07–4.84).
Using Kaplan–Meier and univariate Cox regression analysis, we
also evaluated whether a combination of all markers could be more
predictive of BCR than EGFR alone. We used an unsupervised
hierarchical clustering analysis to organise patient core staining.
This method separated patients into five groups (Figure 5A).
A Kaplan–Meier analysis was performed to assess the association
of these patient groups and BCR (Figure 5B). Indeed, the unsuper-
vised analysis revealed prognostically relevant patient groups
Table 3 Spearman’s correlation between markers
EGFR P-EGFR Her2 P-Her2 ErbB3 PTEN P-PTEN PI3K PAKT P65 Cyto P-p65 p65 Nuc
EGFR
Rho 1 0.625 0.424 0.624 0.565 0.222 0.631 0.608 0.666 0.312  0.028  0.047
P 0000 0.08 0 0 0 0.013 0.825 0.717
p-EGFR
Rho 0.625 1 0.571 0.727 0.419 0.438 0.697 0.715 0.685 0.413 0.098 0.034
P 0 0 0 0.001 0 0 0 0 0.001 0.444 0.791
Her2
Rho 0.424 0.571 1 0.45 0.379 0.523 0.358 0.599 0.382 0.228 0.166 0.017
P 0.001 0 0 0.002 0 0.004 0 0.002 0.073 0.194 0.896
p-Her2
Rho 0.624 0.727 0.45 1 0.416 0.197 0.473 0.582 0.766 0.306 0.036  0.06
P 0 0 0 0.001 0.122 0 0 0 0.015 0.778 0.639
ErbB3
Rho 0.565 0.419 0.379 0.416 1 0.189 0.483 0.579 0.497 0.236  0.125  0.146
P 0 0.001 0.002 0.001 0.138 00 0 0.062 0.33 0.254
PTEN
Rho 0.222 0.438 0.523 0.197 0.189 1 0.323 0.592 0.129 0.419 0.232 0.075
P 0.08 00 0.122 0.138 0.01 0 0.313 0.001 0.067 0.56
P-PTEN
Rho 0.631 0.697 0.358 0.473 0.483 0.323 1 0.704 0.592 0.369 0.158 0.022
P 0 0 0.004 0 0 0.01 0 0 0.003 0.215 0.863
PI3K
Rho 0.608 0.715 0.599 0.582 0.579 0.592 0.704 1 0.586 0.432 0.208  0.026
P 00 0 00 00 00 0.102 0.841
P-AKT
Rho 0.666 0.685 0.382 0.766 0.497 0.129 0.592 0.586 1 0.301 0.038 0.019
P 0 0 0.002 0 0 0.313 0 0 0.016 0.768 0.884
p65 cyto
Rho 0.312 0.413 0.228 0.306 0.236 0.419 0.369 0.432 0.301 1 0.528 0.115
P 0.013 0 0.073 0.015 0.062 0.001 0.003 0 0.016 0 0.371
P-p65
Rho  0.028 0.098 0.166 0.036  0.125 0.232 0.158 0.208 0.038 0.528 1 0.121
P 0.825 0.444 0.194 0.778 0.33 0.067 0.215 0.102 0.768 0 0.343
p65 Nuc
Rho  0.047 0.034 0.017  0.06  0.146 0.075 0.022  0.026 0.019 0.115 0.121 1
P 0.717 0.791 0.896 0.639 0.254 0.56 0.863 0.841 0.884 0.371 0.343
Abbreviations: p65 Cyto¼cytoplasmic staining of p65; p65 Nuc¼nuclear p65 staining; P-¼phospho-; Rho¼Spearman’s coefficient correlation. Significant correlations
(Po0.05) are indicated by bold numbers.
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s(P¼0.003, log rank). Interestingly, this combination of multiple
markers does not correlate with any clinicopathological para-
meters and suggests that the combination may provide a new,
clinically useful, independent prognostic parameter. Indeed, in
Cox multivariate analysis, when clinical variables (Gleason score,
margin status and pathological stage) were taken in the model,
only EGFR and the multiple marker combination remained an
independent predictive variable of BCR (Table 5).
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Figure 4 Kaplan–Meier analysis of the ErbB/PI3K/Akt/NF-kB signalling pathway. Kaplan–Meier curves of BCR-free survival in 63 patients with prostate
cancer. Each individual marker is indicated in the graph. Significance (P) is indicated by log rank.
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No significant association of the proteins tested was obtained, with
the exception of p-PTEN (Table 4, HR¼0.02, P¼0.046). No
significant association of p-PTEN and survival was obtained in
multivariate analysis. However, the significance of this result
should be taken into consideration with the relatively low
mortality rate (n¼9) in this cohort of radical prostatectomy
patients.
DISCUSSION
In prostate cancer cells, the sequential signalling events involved in
the constitutive activation of NF-kB have been analysed in vitro
using cell lines (Sumitomo et al, 1999; Suh and Rabson, 2004;
Le Page et al, 2005a,b). Previously, it has been shown that in the
hormone-independent PC-3 cell line, EGFR and Her-2 synergisti-
cally induce the activation of NF-kB through two distinct signalling
pathways (Le Page et al, 2005a). Using selective tyrphostin
inhibitors, it has been shown that EGFR activates NF-kB through
a mechanism involving the phosphorylation of IkBa on serine
32/36, thereby altering the nuclear translocation of p65. On the
other hand, Her-2 activates a signalling pathway that does not
affect the phosphorylation of IkBa on N-terminal serines 32/36.
In this study, we attempted to extend these observations to
confirm whether EGFR and Her-2 are involved in the constitutive
activation of PI3K/Akt and NF-kB signalling pathways in prostate
cancer tissues. We found that expressions of EGFR and Her-2 are
highly correlated, which makes interpretation difficult for each
individual marker on the signalling pathway. Nevertheless, EGFR,
Her-2 and ErbB3 alone were correlated with the activation of Akt
but not with the nuclear expression of p65. However, combined
EGFR and Her-2 significantly correlated with the presence of
nuclear p65, supporting our in vitro observation in PC-3 cells
showing a synergistic effect of EGFR and Her-2 on NF-kB
activation (Le Page et al, 2005b). This is the first time that a
correlation between ErbB signalling and NF-kB activation has been
assessed and validated in cancer tissues.
We observed that proteins associated with cell signalling, such
as PTEN, p-PTEN, p-Akt and PI3K, correlated with the expression
level of EGFR, Her-2 and ErbB3 receptors (Table 3). The
expression of PI3K was also strongly associated with PTEN and
p-PTEN expression. One could hypothesise that when more PI3K is
present in the cell, more PTEN is required to deactivate this kinase.
Surprisingly, we also observed a direct correlation between p-Akt
and PTEN, although this did not reach significance (P¼0.07).
A similar observation has already been reported in prostate cancer
tissues, although the reason for this remains unclear (Bedolla et al,
2007; Jendrossek et al, 2008) and contrasts with in vitro cell line
observations in which PTEN expression is inversely correlated with
activation of PI3K and Akt. Here, we also observed a positive
correlation between p-Akt and p-PTEN. A possible explanation is
that, although PTEN would be normally expected to downregulate
p-Akt through PI3K, this is counterbalanced by a concomitant
inhibition of PTEN by higher levels of pPTEN, which is itself
functioning as a negative regulator, thus allowing the observed
higher levels of PI3K and pAkt seen in tissues. This hypothesis
would require further experimentation for validation.
We also found that EGFR, Her-2 and ErbB3 are strongly
correlated and associated with the activation of phospho-Akt,
which suggests that these receptors share similar signalling
pathways as reported by in vitro analysis in cell lines (Yarden,
2001; Jorissen et al, 2003). As a consequence, a therapeutic strategy
targeting one receptor may not be sufficient, as any receptor may
compensate for another’s inactivity. Moreover, signalling pathways
are complex integrated networks, which render single therapeutic
strategies less effective. A supporting argument for this hypothesis
is that the activities of EGFR antagonists have not been impressive
as a single agent. Numerous clinical trials are currently underway
in cohorts of patients with breast and prostate carcinoma to
investigate new agents capable of blocking multiple family
members such as lapatinib (Bublil and Yarden, 2007). Our study
suggests that such inhibitors may be useful in prostate cancer
patients.
The present study also analysed and compared the prognostic
value of the total expression of EGFR, Her-2 and ErbB3 receptors,
as well as their activated forms in a series of primary prostate
cancer specimens. The downstream signalling molecules PI3K,
PTEN, phospho-PTEN and activated Akt were also analysed. A
number of previous studies have already reported the association
of EGFR, Her-2 and ErbB3 with PSA biochemical recurrence in
prostate cancer patients (Visakorpi et al, 1992; Kuhn et al, 1993;
Fox et al, 1994; Di Lorenzo et al, 2004; Hernes et al, 2004; Zellweger
et al, 2005; Shah et al, 2006; Schlomm et al, 2007). In line with
these previous studies, we found that EGFR and ErbB3 (Di Lorenzo
et al, 2002; Hernes et al, 2004; Schlomm et al, 2007) are also
associated with PSA recurrence. Reports on the association of
Her-2 and BCR on survival are controversial (Kuhn et al, 1993;
Table 4 Cox regression univariate for EGFR/Her-2/ErbB3 and signaling molecules
BCR OS
95% CI 95% CI
P HR Lower Upper P HR Lower Upper
EGFR 0.005 2.752 1.35 5.612 0.279 2.447 0.484 12.364
P-EGFR 0.036 2.319 1.055 5.1 0.787 0.82 0.196 3.439
Her2 0.587 1.2 0.621 2.318 0.648 1.396 0.333 5.852
P-Her2 0.028 2.267 1.091 4.713 0.344 0.527 0.14 1.986
ErbB3 0.047 2.221 1.009 4.889 0.576 1.58 0.318 7.845
PTEN 0.933 1.029 0.532 1.99 0.139 3.502 0.664 18.461
P-PTEN 0.683 1.152 0.583 2.276 0.046 0.202 0.042 0.976
PI3K 0.222 1.504 0.782 2.893 0.393 1.777 0.476 6.64
P-Akt 0.064 1.867 0.964 3.612 0.641 0.71 0.168 2.997
p65 Cyto 0.304 1.452 0.713 2.954 0.39 1.997 0.412 9.686
P-p65 0.785 1.098 0.561 2.146 0.646 0.734 0.196 2.751
p65 Nuc 0.034 2.786 1.081 7.182 0.349 30.772 0.024 NR
P-EGFR/P-Her2 0.122 0.78 0.568 1.069 0.37 0.738 0.38 1.434
CLUSTER 0.103 1.241 0.957 1.609 0.808 0.928 0.509 1.692
Abbreviations: HR¼hazard ratio; BCR¼biochemical recurrence; OS¼overall survival. Significant correlations (Po0.05) are indicated by bold numbers.
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sSignoretti et al, 2000; Di Lorenzo et al, 2004; Hernes et al, 2004;
Edwards et al, 2006; Isharwal et al, 2008) and are likely because of
the different types of cohorts studied. In our study, we found that
Her-2 was not associated with BCR. However, the phosphorylated
tyrosine 1248 of Her-2 was associated with BCR, suggesting that
IHC evaluation of the phosphorylated form is better than the
standard Her-2 test, which is not clinically used for prostate cancer
patients because of a lack of reliability and association with
outcome. Interestingly, similar results have been found in breast
cancer tissue (Thor et al, 2000; Cicenas et al, 2006; Frogne et al,
2009) when staining of tyrosine 1221/1222 was compared with that
of total Her-2. Further studies in larger cohorts would be necessary
to validate this initial observation and determine the validity of
phospho-Her-2 staining for clinical use in prostate cancer.
When individually compared with each other, the marker that
most significantly correlated with PSA recurrence was EGFR. It
showed a hazard ratio similar to nuclear p65. Multivariate analysis
suggests that EGFR and p65 are two independent prognostic
indicators in prostate cancer tissue, which also supports previous
reports analysing these two markers separately. Therefore, EGFR
and p65 may be interesting markers to help stratify patients for
personalised therapy. However, only EGFR was an independent
marker in multivariate analysis when Gleason, margin status and
pathological stage were included in the model. As EGFR and p65
seem to be strong markers of recurrence in prostate cancer cells,
further studies in larger cohorts would be of major interest to evaluate
the clinical relevance of these two markers in prostate cancer tissues.
Analysis of the expression level of PTEN and its inactivated
phosphorylated form showed that neither correlated with BCR in
patients. This result supports other reports showing no significant
association between PTEN expression and biochemical recurrence
(Bedolla et al, 2007; Jendrossek et al, 2008; McCall et al, 2008), and
also conflicts with other studies showing a significant association
between low cytoplasmic PTEN and outcome (McCall et al, 2008)
in a patient cohort with late relapse (430 months). Altogether,
these results suggest that PTEN may only be a prognosis marker
for advanced prostate cancer patients. Surprisingly, we did not
notice any correlation between a decreased expression of PTEN
and an increased activation of Akt, rather we did find a correlation
between PI3K and Akt activation. However, this also confirms the
previous results obtained in prostate cancer tissues (Bedolla et al,
2007; Jendrossek et al, 2008). We found that the inactivation of
PTEN, as determined by the detection of N-terminal phosphory-
lation, was more significantly correlated with the increased activa-
tion of Akt. This result suggests that the loss of PTEN expression is
not the only event regulating the activation of Akt in prostate
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Figure 5 EGFR, Her-2 and PI3K/Akt/NF-kB signalling pathways in an unsupervised hierarchical analysis and association with outcome. (A) Unsupervised
hierarchical clustering. Each column represents a patient. Each row represents a marker staining as indicated on the left side. Grey colour represents weak
marker staining, black represents strong marker staining. (B) Kaplan–Meier curve analysis. The five groups of patients identified by unsupervised clustering
(clusters 1, 2, 3, 4 and 5 in Figure 4A) were analysed using Kaplan–Meier analysis for biochemical recurrence-free survival. P¼0.003, significance (P)i s
indicated by log rank.
Table 5 Cox regression multivariate analysis for EGFR and Cluster
P HR 95% CI
EGFR 0.034 2.271 1.066 4.836
Gleason 0.007 1.489 1.115 1.989
Stage 0.503 1.516 0.449 5.116
Margins 0.111 2.722 0.795 9.318
CLUSTER 0.034 1.384 1.025 1.869
Gleason 0.011 1.489 1.095 2.024
Stage 0.112 2.528 0.804 7.944
Margins 0.219 2.033 0.656 6.305
Abbreviations: CI¼confidence interval; HR¼hazard ratio; EGFR¼epidermal
growth factor receptor. Significant correlations (Po0.05) are indicated by bold
numbers.
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scancer tissues. Other upstream molecular events, such as activa-
tion of kinases responsible for the phosphorylation of PTEN, may
also be involved.
Interestingly, in this study, we applied a non-supervised
hierarchical analysis of our set of markers, which identified five
prognostically significant groups of patients. The same approach
has already been successfully used for stratification of breast
cancer tissues in TMAs, allowing the classification of breast
cancers into clinically relevant prognostic groups. Cells from the
patient group with the highest risk of recurrence (group 5,
Figure 4) stained positive for all markers tested, which reinforces
the importance of the cellular and molecular interaction of each
marker in prostate cancer progression even if individually they do
not reach prognostic significance.
In summary, our multimarker analysis provides evidence that
EGFR, Her-2 and ErbB3 are involved in the constitutive activation
of Akt and NF-kB, which validates, for the first time in prostate
cancer samples, previous in vitro data obtained in cell lines. The
importance of PTEN in the constitutive activation of Akt was not
validated in our cohort of patients. In addition, we show evidence
that the ErbB/PI3K/Akt/ NF-kB signalling pathway is involved in
prostate cancer progression and that a multiple marker approach
identifying active signalling pathways may be prognostically
more relevant than single markers. Further studies including
larger patient cohorts should be investigated to confirm these
initial results.
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